Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

被引：0
|
作者：
Josep M. Llovet
Arndt Vogel
David C. Madoff
Richard S. Finn
Sadahisa Ogasawara
Zhenggang Ren
Kalgi Mody
Jerry J. Li
Abby B. Siegel
Leonid Dubrovsky
Masatoshi Kudo
机构：
[1] Tisch Cancer Institute,Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai
[2] University of Barcelona,Translational Research in Hepatic Oncology, IDIBAPS, Hospital Clinic Barcelona
[3] Institució Catalana d’Estudis Avançats (ICREA),Graduate School of Medicine
[4] Hannover Medical School,School of Medicine
[5] Yale School of Medicine and Yale Cancer Center/Smilow Cancer Hospital,undefined
[6] David Geffen School of Medicine at UCLA,undefined
[7] Chiba University,undefined
[8] Zhongshan Hospital Fudan University,undefined
[9] Eisai Inc,undefined
[10] Merck & Co.,undefined
[11] Inc,undefined
[12] Kindai University,undefined
来源：
CardioVascular and Interventional Radiology | 2022年 / 45卷
关键词：
Intermediate-stage hepatocellular carcinoma; Lenvatinib; Pembrolizumab; Transarterial chemoembolization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：405 / 412
页数：7
相关论文
共 50 条
  • [1] Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 45 (04) : 405 - 412
  • [2] LEAP-012 TRIAL IN PROGRESS: PEMBROLIZUMAB, LENVATINIB, AND TRANSARTERIAL CHEMOEMBOLIZATION COMBINATION THERAPY FOR INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA NOT AMENABLE TO CURATIVE TREATMENT
    Vogel, Arndt
    Llovet, Josep M.
    El-Khoueiry, Anthony B.
    Madoff, David C.
    Finn, Richard
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    HEPATOLOGY, 2020, 72 : 697A - 698A
  • [3] LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet, J. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Madoff, D. C.
    Finn, R. S.
    Ogasawara, S.
    Ren, Z.
    Mody, K.
    Li, J. Jing
    Siegel, A. B.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S702 - S703
  • [4] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
    Ogasawara, S.
    Llovet, J.
    El-Khoueiry, A.
    Vogel, A.
    Madoff, D.
    Finn, R.
    Ren, Z.
    Modi, K.
    Li, J.
    Siegel, A.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S124 - S125
  • [5] LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
    Llovet, J.
    Finn, R. S.
    Ren, Z.
    Guo, Y.
    Han, G.
    Lin, H.
    Zheng, J.
    Ogasawara, S.
    Li, H.
    Kim, J. H.
    Zhao, H.
    Li, C.
    Madoff, D. C.
    Ghobrial, R. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Peng, X.
    Mody, K.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1229 - 1229
  • [7] Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2025, 14 (01) : 1 - 7
  • [8] Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma
    Xiang, Yan-Jun
    Wang, Kang
    Yu, Hong-Ming
    Li, Xiao-Wei
    Cheng, Yu-Qiang
    Wang, Wei-Jun
    Feng, Jin-Kai
    Bo, Meng-Han
    Qin, Ying-Yi
    Zheng, Yi-Tao
    Shan, Yun-Feng
    Zhou, Li-Ping
    Zhai, Jian
    Cheng, Shu-Qun
    HEPATOLOGY RESEARCH, 2022, 52 (08) : 721 - 729
  • [9] Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Zhou, Qunfang
    Tuo, Fei
    Li, Ruixia
    Wang, Xiaohui
    Wang, Juncheng
    Huang, Zhimei
    Chen, Minshan
    Huang, Jinhua
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012) : a multicentre, randomised, double-blind, phase 3 study
    Kudo, Masatoshi
    Ren, Zhenggang
    Guo, Yabing
    Han, Guohong
    Lin, Hailan
    Zheng, Jinfang
    Ogasawara, Sadahisa
    Kim, Ji Hoon
    Zhao, Haitao
    Li, Chuan
    Madoff, David C.
    Ghobrial, R. Mark
    Kawaoka, Tomokazu
    Ikeda, Masafumi
    Gerolami, Rene
    Kumada, Hiromitsu
    El-Khoueiry, Anthony B.
    Vogel, Arndt
    Peng, Xiang
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    Llovet, Josep M.
    LANCET, 2025, 405 (10474): : 203 - 215
12345